Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
SK Biopharmaceuticals is an innovative South Korean pharmaceutical company dedicated to the research and development of novel medicines. The company develops and markets therapies for CNS disorders and oncology, aiming to sustainably improve the quality of life for patients worldwide.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
SK Biopharmaceuticals is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
SK Biopharmaceuticals last reported quarterly earnings on 8/5/2026 (Q2 2026). Earnings per share (EPS) came in at 581.55 KRW.
Across its last 5 earnings reports, SK Biopharmaceuticals stock moved by ±5% on average the following day. The largest reaction was +17.2% on 02/06/2025; 4 of 5 reactions were positive.
SK Biopharmaceuticals has beaten analyst EPS estimates in 5 of its last 5 evaluated quarters (beat rate: 100%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.